The event will include presentations from Tourmaline's leadership team and Dr. Marc Bonaca, a cardiologist and vascular med Tourmaline Bio, Inc. ( (TRML) ) has released its Q3 earnings.
Phase 2 TRANQUILITY trial in patients with elevated high-sensitivity C-reactive protein and chronic kidney disease over-enrolled to 143 total ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback